Mucormycosis following COVID19: clinical case and literature review

Clinical Microbiology and Antimicrobial Chemotherapy. 2021; 23(3):255-262

​ Khostelidi S.N., Zaytsev V.A., Pelikh E.V., Yashina E.V., Rodionova O.N., Bogomolova T.S., Avdeenko Yu.L., Klimko N.N.
10.36488/cmac.2021.3.255-262
mucormycosis invasive fungal infection rhino-orbital mucormycosis zygomycosis COVID-19 Rhizopus spp SARS-CoV-2
Section
Diseases and Pathogens
Type
Review
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2021; 23(3):255-262

Abstract

Mucormycosis is one of the most aggressive invasive mycoses. The mortality rate of patients with mucormycosis, depending on clinical form and background disease, varies from 30% to 100%. This article provides the first description of mucormycosis in Russia after infection caused by SARS-CoV-2, as well as a review of literature reports on mucormycosis in patients with COVID-19 (as of September 2021).

Sofya N. Khostelidi

North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russia

Zaytsev V.A.

Clinical Emergency Care Hospital

Pelikh E.V.

Clinical Emergency Care Hospital

Yashina E.V.

Clinical Emergency Care Hospital

Rodionova O.N.

Volgograd State Medical University, Volgograd, Russia

Bogomolova T.S.

North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russia

Avdeenko Yu.L.

North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russia

Nikolay N. Klimko

North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russia

  • 1. Zhu X., Ge Y., Wu T., Zhao K., Chen Y., Wuet B., et al. Coinfection with respiratory pathogens among COVID-2019 cases. Virus Res. 2020;285:198005. DOI: 10.1016/j.virusres.2020.198005
  • 2. Donnelly J.P., Chen S.C., Kauffman C.A., Steinbach W.J., Baddley J.W., Verweij P.E., et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71:1367-1376. DOI: 10.1093/cid/ciz1008
  • 3. Interim guidelines “Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)”. Version 10, 02/08/2021. Available at: https://static-0.minzdrav.gov.ru. Russian.
  • 4. Bhatt K., Agolli A., Patel M.H., Garimella R., Devi M., Garcia E., et al. High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections. Discoveries (Craiova). 2021;9(1):e126. DOI: 10.15190/d.2021.5
  • 5. INDIA NEWS. India reported over 45,000 black fungus cases so far, says Mandaviya in RS. Available at: www.hindustantimes.com/india-news/india-reported-over45-000-black-fungus-cases-so-far-says-mandaviyainrs-101626781531292.html. Accessed Jul 20, 2021.
  • 6. Kimmig L.M., Wu D., Gold M., Pettit N.N., Pitrak D., Mueller J., et al. IL-6 inhibition in critically Ill COVID-19 patients is associated with increased secondary infections. Front Med (Lausanne). 2020;7:583897. DOI: 10.3389/fmed.2020.583897
  • 7. Hanley B., Naresh K.N., Roufosse C., Nicholson A., Weir J., Cookeet G., et al. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. Lancet Microbe. 2020;1(6):e245-e253. DOI: 10.1016/S2666-5247(20)30115-4
  • 8. Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med. 2020. DOI: 10.1016/j.ajem.2020.09.032
  • 9. Placik D.A., Taylor W.L., Wnuk N.M. Bronchopleural fistula development in the setting of novel therapies for acute respiratory distress syndrome in SARS-CoV-2 pneumonia. Radiol Case Rep. 2020;15(11):2378-2381. DOI: 10.1016/j.radcr.2020.09.026
  • 10. Mehta S., Pandey A. Rhino-orbital mucormycosis associated with COVID-19. Cureus. 2020;12(9):e10726. DOI: 10.7759/cureus.10726
  • 11. Monte Junior E.S.D., Santos M.E.L.D., Ribeiro I.B., Luz G.O., Baba E.R., Hirsch B.S., et al. Rare and fatal gastrointestinal mucormycosis (Zygomycosis) in a COVID-19 patient: a case report. Clin Endosc. 2020;53(6):746-749. DOI: 10.5946/ce.2020.180
  • 12. Pasero D., Sanna S., Liperi C., Piredda D., Branca G.P., Casadio L., et al. Challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis. Infection. 2020;49:1-6. DOI: 10.1007/s15010-020-01561-x
  • 13. Mekonnen Z.K., Ashraf D.C., Jankowski T., Grob S.R., Vagefi M.R., Kersten R.C., et al. Acute invasive rhino-orbital mucormycosis in a patient with COVID-19-Associated Acute Respiratory Distress Syndrome. Ophthalmic Plast Reconstr Surg. 2021;37(2):e40-e80. DOI: 10.1097/IOP.0000000000001889
  • 14. Zurl C., Hoenigl M., Schulz E., Hatzl S., Gorkiewicz G., Krause R., et al. Autopsy proven pulmonary mucormycosis due to Rhizopus microspores in a critically ill COVID-19 patient with underlying hematological malignancy. J Fungi (Basel). 2021;7(2):88. DOI: 10.3390/jof7020088
  • 15. Bellanger A.P., Navellou J.C., Lepiller Q., Brion A., Brunel A.S., Millon L., et al. Mixed mold infection with Aspergillus fumigatus and Rhizopus microspores in a Severe Acute Respiratory syndrome Coronavirus 2 (SARS-CoV-2) patient. Infect Dis Now. 2021;51(7):633-635. DOI: 10.1016/j.idnow.2021.01.010
  • 16. Sen M., Lahane S., Lahane T.P., Parekh R., Honavar S.G. Mucor in a viral land: a tale of two pathogens. Indian J Ophthalmol. 2021;69(2):244-252. DOI: 10.4103/ijo.IJO_3774_20
  • 17. Garg D., Muthu V., Sehgal I.S., Ramachandran R., Kaur H., Bhalla A., Agarwal R., et al. Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): case report and systematic review of literature. Mycopathologia. 2021:1-10. DOI: 10.1007/s11046-021-00528-2
  • 18. Waizel-Haiat S., Guerrero-Paz J.A., Sanchez-Hurtado L., Calleja-Alarcon S., Romero-Gutierrez L. A Case of fatal rhino-orbital mucormycosis associated with new onset diabetic ketoacidosis and COVID-19. Cureus. 2021;13(2):e13163. DOI: 10.7759/cureus.13163
  • 19. Kanwar A., Jordan A., Olewiler S., Wehberg K., Cortes M., Jackson B.R. A fatal case of Rhizopus azygosporus pneumonia following COVID-19. J Fungi (Basel). 2021;7(3):174. DOI: 10.3390/jof7030174
  • 20. Moorthy A., Gaikwad R., Krishna S., Hegde R., Tripathi K.K., Kale P.G., et al. SARS-CoV-2, uncontrolled diabetes and corticosteroids – an unholy trinity in invasive fungal infections of the maxillofacial region? A retrospective, multi-centric analysis. J Maxillofac Oral Surg. 2021:1-8. DOI: 10.1007/s12663-021-01532-1
  • 21. Karimi-Galougahi M., Arastou S., Haseli S. Fulminant mucormycosis complicating coronavirus disease 2019 (COVID-19). Int Forum Allergy Rhinol. 2021;11(6):1029-1030. DOI: 10.1002/alr.22785
  • 22. Dallalzadeh L.O., Ozzello D.J., Liu C.Y., Kikkawa D.O., Korn B.S. Secondary infection with rhino-orbital cerebral mucormycosis associated with COVID-19. Orbit. 2021;1-4. DOI: 10.1080/01676830.2021.1903044
  • 23. Sarkar S., Gokhale T., Choudhury S.S., Deb A.K. COVID-19 and orbital mucormycosis. Indian J Ophthalmol. 2021;69(4):1002-1004. DOI: 10.4103/ijo.IJO_3763_20
  • 24. Kumar M., Sarma D.K., Shubham S., Kumawat M., Verma V., Singhet B., et al. Mucormycosis in COVID-19 pandemic: risk factors and linkages. Curr Res Microb Sci. 2021;2:100057. DOI: 10.1016/j.crmicr.2021.100057
  • 25. Prakash H., Skiada A., Paul R.A., Chakrabarti A., Rudramurthy S.M. Connecting the dots: interplay of pathogenic mechanisms between COVID-19 disease and mucormycosis. J Fungi (Basel). 2021;7(8):616. DOI: 10.3390/jof7080616
  • 26. Rudramurthy S.M., Hoenigl M., Meis J.F., Cornely O.A., Muthu V., Gangneux J.P., et al. ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries. Mycoses. 2021;64(9):1028-1037. DOI: 10.1111/myc.13335
  • 27. Prakash H., Singh S., Rudramurthy S.M., Singh P., Mehta N., Shaw D., Ghosh A.K. An aero mycological analysis of Mucormycetes in indoor and outdoor environments of northern India. Med Mycol. 2020;58(1):118123. DOI: 10.1093/mmy/myz031
  • 28. Hoenigl M., Seidel D., Carvalho A., Rudramurthy S.M., Arastehfar A., Gangneux J.P., et al. The emergence of COVID-19 associated mucormycosis: analysis of cases from 18 countries. Lancet (preprint). DOI: 10.2139/ssrn.3844587
  • 29. Shrivastava A.K., and members of the Collaborative OPAIIJO Study on Mucormycosis in COVID-19 (COSMIC) Study Group (2021). Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India – Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1. IIndian J Ophthalmol. 2021;69(7):1670-1692. DOI: 10.4103/ijo.IJO_1565_21
  • 30. Cornely O.A., Alastruey-Izquierdo A., Arenz D., Chen S.C.A., Dannaoui E., Hochhegger B., et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12):e405-e421. DOI: 10.1016/S1473-3099(19)30312-3
  • 31. Duarte R.F., López-Jiménez J., Cornely O.A., Laverdiere M., Helfgott D., Haider S., et al. Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia. Antimicrob Agents Chemother. 2014;58(10):5758-5765. DOI: 10.1128/AAC.03050-14
Views
0 Abstract
0 PDF
0 Crossref citations
Shared